|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
1,770,000,000 |
Market
Cap: |
339.66(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$137.6 - $199.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 173 |
Guru Rank Value : 8 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
349,345 |
349,345 |
811,261 |
1,180,941 |
Total Sell Value |
$61,901,455 |
$61,901,455 |
$143,547,771 |
$200,355,024 |
Total People Sold |
1 |
1 |
9 |
12 |
Total Sell Transactions |
2 |
2 |
13 |
31 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Roberts Rebecca B |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
8,332 |
|
- |
|
Waddell Frederick H |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
23,562 |
|
- |
|
Liddy Edward M |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
26,683 |
|
- |
|
Tilton Glenn F |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
46,168 |
|
- |
|
Austin Roxanne S |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
121,128 |
|
- |
|
Freyman Thomas C |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
121,355 |
|
- |
|
Burnside William H.l. |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
21,562 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-05-03 |
4 |
S |
$112.40 |
$470,282 |
D/D |
(4,184) |
59,225 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-05-03 |
4 |
OE |
$41.39 |
$173,176 |
D/D |
4,184 |
63,409 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-03-07 |
4 |
D |
$106.70 |
$13,124 |
D/D |
(123) |
59,225 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-03-06 |
4 |
D |
$106.70 |
$37,985 |
D/D |
(356) |
59,348 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-03-05 |
4 |
D |
$105.65 |
$47,331 |
D/D |
(448) |
59,704 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-03-02 |
4 |
D |
$108.41 |
$87,812 |
D/D |
(810) |
60,152 |
|
- |
|
Gonzalez Richard A |
Chairman of the Board and CEO |
|
2021-03-02 |
4 |
OE |
$54.86 |
$9,332,399 |
D/D |
170,113 |
546,710 |
|
- |
|
Stewart Jeffrey Ryan |
SVP, US Commercial Operations |
|
2021-03-01 |
4 |
S |
$108.59 |
$1,495,576 |
D/D |
(13,773) |
50,969 |
|
- |
|
Sorg Elaine K. |
SVP, US Commercial Operations |
|
2021-03-01 |
4 |
S |
$108.61 |
$916,642 |
D/D |
(8,440) |
17,595 |
|
- |
|
Richmond Timothy J. |
EVP, Chief HR Officer |
|
2021-03-01 |
4 |
S |
$108.59 |
$2,119,041 |
D/D |
(19,514) |
0 |
|
- |
|
Gonzalez Richard A |
Chairman of the Board and CEO |
|
2021-03-01 |
4 |
S |
$108.61 |
$18,476,204 |
D/D |
(170,113) |
376,597 |
|
- |
|
Stewart Jeffrey Ryan |
SVP, US Commercial Operations |
|
2021-02-28 |
4 |
D |
$107.74 |
$1,180,507 |
D/D |
(10,957) |
64,742 |
|
- |
|
Sorg Elaine K. |
SVP, US Commercial Operations |
|
2021-02-28 |
4 |
D |
$107.74 |
$723,582 |
D/D |
(6,716) |
26,035 |
|
- |
|
Gosebruch Henry O |
EVP, Chief Strategy Officer |
|
2021-02-28 |
4 |
D |
$107.74 |
$2,460,027 |
D/D |
(22,833) |
48,711 |
|
- |
|
Michael Robert A. |
EVP, Chief Financial Officer |
|
2021-02-28 |
4 |
D |
$107.74 |
$1,509,006 |
D/D |
(14,006) |
37,877 |
|
- |
|
Hudson Thomas J |
SVP, R&D and CSO |
|
2021-02-28 |
4 |
D |
$107.74 |
$833,908 |
D/D |
(7,740) |
29,372 |
|
- |
|
Severino Michael |
Vice Chairman |
|
2021-02-28 |
4 |
D |
$107.74 |
$3,132,756 |
D/D |
(29,077) |
103,835 |
|
- |
|
Richmond Timothy J. |
EVP, Chief HR Officer |
|
2021-02-28 |
4 |
D |
$107.74 |
$1,672,556 |
D/D |
(15,524) |
19,514 |
|
- |
|
644 Records found
|
|
Page 10 of 26 |
|
|